588 related articles for article (PubMed ID: 15097300)
1. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
2. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.
Davey RT; Murphy RL; Graziano FM; Boswell SL; Pavia AT; Cancio M; Nadler JP; Chaitt DG; Dewar RL; Sahner DK; Duliege AM; Capra WB; Leong WP; Giedlin MA; Lane HC; Kahn JO
JAMA; 2000 Jul; 284(2):183-9. PubMed ID: 10889591
[TBL] [Abstract][Full Text] [Related]
3. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
[TBL] [Abstract][Full Text] [Related]
4. Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.
Lalezari JP; Beal JA; Ruane PJ; Cohen CJ; Jacobson EL; Sundin D; Leong WP; Raffanti SP; Wheeler DA; Anderson RD; Keiser P; Schrader SR; Goodgame JC; Steinhart CR; Murphy RL; Wolin MJ; Smith KA
HIV Clin Trials; 2000; 1(3):1-15. PubMed ID: 11590500
[TBL] [Abstract][Full Text] [Related]
5. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial.
Molina JM; Rizzardini G; Orrell C; Afani A; Calmy A; Oka S; Hinestrosa F; Kumar P; Tebas P; Walmsley S; Grandhi A; Klopfer S; Gendrano I; Eves K; Correll TA; Fox MC; Kim J
Lancet HIV; 2024 Jun; 11(6):e369-e379. PubMed ID: 38734015
[TBL] [Abstract][Full Text] [Related]
6. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial.
Levy Y; Durier C; Krzysiek R; Rabian C; Capitant C; Lascaux AS; Michon C; Oksenhendler E; Weiss L; Gastaut JA; Goujard C; Rouzioux C; Maral J; Delfraissy JF; Emilie D; Aboulker JP;
AIDS; 2003 Feb; 17(3):343-51. PubMed ID: 12556688
[TBL] [Abstract][Full Text] [Related]
7. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Losso MH; Belloso WH; Emery S; Benetucci JA; Cahn PE; Lasala MC; Lopardo G; Salomon H; Saracco M; Nelson E; Law MG; Davey RT; Allende MC; Lane HC
J Infect Dis; 2000 May; 181(5):1614-21. PubMed ID: 10823761
[TBL] [Abstract][Full Text] [Related]
8. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).
Kilby JM; Bucy RP; Mildvan D; Fischl M; Santana-Bagur J; Lennox J; Pilcher C; Zolopa A; Lawrence J; Pollard RB; Habib RE; Sahner D; Fox L; Aga E; Bosch RJ; Mitsuyasu R;
J Infect Dis; 2006 Dec; 194(12):1672-6. PubMed ID: 17109338
[TBL] [Abstract][Full Text] [Related]
9. Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV.
Lévy Y; Thiébaut R; Gougeon ML; Molina JM; Weiss L; Girard PM; Venet A; Morlat P; Poirier B; Lascaux AS; Boucherie C; Sereni D; Rouzioux C; Viard JP; Lane C; Delfraissy JF; Sereti I; Chêne G;
AIDS; 2012 Mar; 26(6):711-20. PubMed ID: 22301410
[TBL] [Abstract][Full Text] [Related]
10. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 therapy in patients with HIV infection.
; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulators as adjunctive therapy for HIV-1 infection.
Pett SL; Emery S
J Clin Virol; 2001 Oct; 22(3):289-95. PubMed ID: 11564594
[TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
14. Role of interleukin-2 in patients with HIV infection.
Pett SL; Kelleher AD; Emery S
Drugs; 2010 Jun; 70(9):1115-30. PubMed ID: 20518579
[TBL] [Abstract][Full Text] [Related]
15. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial.
Porter BO; Anthony KB; Shen J; Hahn B; Keh CE; Maldarelli F; Blackwelder WC; Lane HC; Kovacs JA; Davey RT; Sereti I
AIDS; 2009 Jan; 23(2):203-12. PubMed ID: 19098490
[TBL] [Abstract][Full Text] [Related]
16. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
Tambussi G; Ghezzi S; Nozza S; Vallanti G; Magenta L; Guffanti M; Brambilla A; Vicenzi E; Carrera P; Racca S; Soldini L; Gianotti N; Murone M; Veglia F; Poli G; Lazzarin A
J Infect Dis; 2001 May; 183(10):1476-84. PubMed ID: 11319683
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
[TBL] [Abstract][Full Text] [Related]
19. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Kovacs JA; Vogel S; Albert JM; Falloon J; Davey RT; Walker RE; Polis MA; Spooner K; Metcalf JA; Baseler M; Fyfe G; Lane HC
N Engl J Med; 1996 Oct; 335(18):1350-6. PubMed ID: 8857018
[TBL] [Abstract][Full Text] [Related]
20. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
